BRPI1011612A2 - composto, composição farmacêutica, e, métodos para induzir apoptose em uma célula, para tratar câncer, e para tratar uma doença autoimune. - Google Patents

composto, composição farmacêutica, e, métodos para induzir apoptose em uma célula, para tratar câncer, e para tratar uma doença autoimune.

Info

Publication number
BRPI1011612A2
BRPI1011612A2 BRPI1011612A BRPI1011612A BRPI1011612A2 BR PI1011612 A2 BRPI1011612 A2 BR PI1011612A2 BR PI1011612 A BRPI1011612 A BR PI1011612A BR PI1011612 A BRPI1011612 A BR PI1011612A BR PI1011612 A2 BRPI1011612 A2 BR PI1011612A2
Authority
BR
Brazil
Prior art keywords
treating
cell
compound
methods
pharmaceutical composition
Prior art date
Application number
BRPI1011612A
Other languages
English (en)
Inventor
d alexander Matthew
G Laporte Matthew
M Condon Stephen
Deng Yijun
Original Assignee
Tetralogic Pharm Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tetralogic Pharm Corp filed Critical Tetralogic Pharm Corp
Publication of BRPI1011612A2 publication Critical patent/BRPI1011612A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BRPI1011612A 2009-05-28 2010-05-27 composto, composição farmacêutica, e, métodos para induzir apoptose em uma célula, para tratar câncer, e para tratar uma doença autoimune. BRPI1011612A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18191409P 2009-05-28 2009-05-28
PCT/US2010/036320 WO2010138666A1 (en) 2009-05-28 2010-05-27 Iap inhibitors

Publications (1)

Publication Number Publication Date
BRPI1011612A2 true BRPI1011612A2 (pt) 2019-09-24

Family

ID=43223066

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1011612A BRPI1011612A2 (pt) 2009-05-28 2010-05-27 composto, composição farmacêutica, e, métodos para induzir apoptose em uma célula, para tratar câncer, e para tratar uma doença autoimune.

Country Status (11)

Country Link
US (1) US8415486B2 (pt)
EP (1) EP2434890A4 (pt)
JP (1) JP5642777B2 (pt)
CN (1) CN102458116B (pt)
AU (1) AU2010254056A1 (pt)
BR (1) BRPI1011612A2 (pt)
CA (1) CA2763638A1 (pt)
EA (1) EA201171415A1 (pt)
NZ (1) NZ596675A (pt)
WO (1) WO2010138666A1 (pt)
ZA (1) ZA201108858B (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006020060A2 (en) 2004-07-15 2006-02-23 Tetralogic Pharmaceuticals Corporation Iap binding compounds
US7517906B2 (en) 2005-02-25 2009-04-14 Tetralogic Pharmaceuticals Corporation Dimeric IAP inhibitors
AU2009293403A1 (en) * 2008-09-17 2010-03-25 Tetralogic Pharmaceuticals Corp. IAP inhibitors
US8283372B2 (en) 2009-07-02 2012-10-09 Tetralogic Pharmaceuticals Corp. 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic
UY33794A (es) 2010-12-13 2012-07-31 Novartis Ag Inhibidores diméricos de las iap
GB201106817D0 (en) 2011-04-21 2011-06-01 Astex Therapeutics Ltd New compound
US20130196927A1 (en) * 2012-01-27 2013-08-01 Christopher BENETATOS Smac Mimetic Therapy
US9980973B2 (en) 2012-10-19 2018-05-29 Astex Therapeutics Limited Bicyclic heterocycle compounds and their uses in therapy
GB201218864D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
GB201218862D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
GB201218850D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
CN103435526B (zh) * 2013-08-22 2015-05-06 天津速研医药科技有限公司 一种维达列汀的合成方法
CN104710510A (zh) * 2013-12-12 2015-06-17 深圳先进技术研究院 Smac蛋白二聚拟合物及其鉴定方法
HUE056297T2 (hu) 2013-12-20 2022-02-28 Astex Therapeutics Ltd Biciklikus heterociklusos vegyületek és ezek terápiában történõ alkalmazása
MA39822A (fr) 2014-04-03 2018-02-06 Janssen Pharmaceutica Nv Dérivés de pyrimidine bicycle

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005228950B2 (en) * 2004-03-23 2012-02-02 Genentech, Inc. Azabicyclo-octane inhibitors of IAP
AR048927A1 (es) * 2004-04-07 2006-06-14 Novartis Ag Compuestos heterociclicos como inhibidores de proteinas de apoptosis (iap); composiciones farmaceuticas que los contienen y su uso en el tratamiento de una enfermedad proliferativa
US20100113326A1 (en) * 2006-07-24 2010-05-06 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
MX2009011783A (es) * 2007-04-30 2009-12-04 Genentech Inc Inhibidores de iap.
AU2009293403A1 (en) * 2008-09-17 2010-03-25 Tetralogic Pharmaceuticals Corp. IAP inhibitors
EA201171414A1 (ru) * 2009-05-28 2012-06-29 Тетралоджик Фармасьютикалз Корп. Ингибиторы белков семейства iap

Also Published As

Publication number Publication date
WO2010138666A1 (en) 2010-12-02
JP2012528187A (ja) 2012-11-12
CN102458116A (zh) 2012-05-16
US8415486B2 (en) 2013-04-09
CA2763638A1 (en) 2010-12-02
NZ596675A (en) 2013-11-29
ZA201108858B (en) 2012-08-29
EA201171415A1 (ru) 2013-01-30
EP2434890A4 (en) 2013-01-02
CN102458116B (zh) 2014-12-31
US20120135990A1 (en) 2012-05-31
AU2010254056A1 (en) 2011-12-15
EP2434890A1 (en) 2012-04-04
JP5642777B2 (ja) 2014-12-17

Similar Documents

Publication Publication Date Title
BRPI1011612A2 (pt) composto, composição farmacêutica, e, métodos para induzir apoptose em uma célula, para tratar câncer, e para tratar uma doença autoimune.
BRPI0906785A2 (pt) Composto, composição farmacêutica, e, métodos para induzir a apoptose em uma célula, para tratar câncer e uma doença autoimune
BRPI0914918A2 (pt) forma de dosagem farmacêutica, e, método para preparar uma forma de dosagem sólida.
LTC2459208I2 (lt) Terapiniai agentai, skirti prieskydinės liaukos hormono lygio sumažinimui
BRPI0817751A2 (pt) método para suprimir a proliferação de células de tumor, e, composição
BR112015001098A2 (pt) composto, composição farmacêutica e método para o tratamento de uma condição de doença.
BRPI0811589A2 (pt) Composição farmacêutica e método para tratar câncer
IL222234A0 (en) Biomarkers for mdm2 inhibitors for use in treating disease
BRPI1011764A2 (pt) composição farmacêutica, e, método para preparar uma composição farmacêutica
CL2013003031A1 (es) Metodo para estratificacion a base de bcma en pacientes con mieloma multiple; anticuerpo anti-bcma.
BRPI1010849A2 (pt) parafuso para ossos.
BR112012018951A2 (pt) composição farmacêutica, combinação farmacêutica e método para o tratamento e\ou prevenção de um câncer e anticorpo
IT1394860B1 (it) Composti farmaceutici
GB0703507D0 (en) Solid pharmaceutical dose
IT1400425B1 (it) Modified snrnas for use in therapy.
BRPI1009919A2 (pt) combinações de pentamidina para tratamento de câncer.
BRPI1013618A2 (pt) pirimidinas substituídas para o tratamento de câncer
BR112012000502A2 (pt) terapia de combinação para o tratamento de diabetes
AP2011005857A0 (en) Tablets for combination therapy.
BRPI0811059A2 (pt) combinação, composição farmacêutica, método para tratar câncer em um animal de sangue quente, e, uso de uma combinação
BR112013033078A2 (pt) partícula, composição farmacêutica, conjunto para o tratamento do câncer e método para o tratamento do câncer em um paciente
BRPI0821248A2 (pt) Inibidores de cinesina como fármacos terapêuticos para câncer
BRPI1007995A2 (pt) orto-aminoamidas para o tratamento de cãncer.
BR112012001959A2 (pt) comprimido,e, método para reproduzir um comprimido
BRPI0818323A2 (pt) composição farmacêutica, uso de uma composição farmacêutica, e, método para tratar câncer.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.